R
Revelle Aesthetics (Formerly NC8)
About Revelle Aesthetics (Formerly NC8)
Revelle Aesthetics is a forward-thinking startup specializing in innovative solutions for cellulite treatment. The company operates in the aesthetic and cosmetic medical market, targeting both professional healthcare providers and individual consumers who seek effective treatments for cellulite.
Led by Annelise Norton, a seasoned biopharmaceutical leader, and Dustin Hacker, an accomplished sales professional with a background in disruptive surgical technologies, Revelle Aesthetics leverages their combined expertise to develop and market cutting-edge products. Their primary focus is on creating smart, effective solutions that address cellulite, a common cosmetic concern.
Revelle Aesthetics employs a business-to-business (B2B) and business-to-consumer (B2C) model. They partner with medical professionals, such as dermatologists and plastic surgeons, to integrate their products into clinical practices. Additionally, they market directly to consumers who are looking for non-invasive, reliable cellulite treatments. This dual approach allows them to capture a broad market segment and drive revenue through multiple channels.
The company generates income by selling their innovative cellulite treatment products to medical professionals and directly to consumers. They also provide training and support to healthcare providers to ensure the effective use of their products, which helps build long-term relationships and repeat business.
Revelle Aesthetics stands out in the market due to its commitment to research and development, ensuring that their solutions are both scientifically backed and highly effective. Their focus on disruptive technologies and strategic market positioning has positioned them for rapid growth and potential acquisition, as evidenced by the successful track records of their leadership team.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jun 2023 | $30M | $120M | Trinity Capital | ↗ |
| DEBTDebt | Apr 2022 | $25M | — | Runway Growth Capital | ↗ |
Growth signals
Latest recorded traffic for Revelle Aesthetics (Formerly NC8) is 1.8K monthly website visits, up 5.9% over the last three months. Revelle Aesthetics (Formerly NC8)'s team declined 30.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Revelle Aesthetics (Formerly NC8) in the Mountain View ecosystem
The Revelle Aesthetics (Formerly NC8) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Runway Growth Capital
Trinity Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Revelle Aesthetics (Formerly NC8) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Revelle Aesthetics (Formerly NC8)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









